{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T10:53:33Z","timestamp":1776336813145,"version":"3.51.2"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T00:00:00Z","timestamp":1725321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To mine and analyze adverse events (AEs) related to proteasome inhibitors in multiple myeloma based on the FDA Adverse Event Reporting System (FAERS), providing references for rational clinical medication.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>AE data related to multiple myeloma proteasome inhibitors were collected from the FAERS from the first quarter of 2010 to the first quarter of 2024. Signal mining of AEs was conducted using the reporting odds ratio method and Bayesian confidence propagation neural network method.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 8,805 reports for bortezomib, 5,264 for carfilzomib, and 8,771 for ixazomib were collected, with corresponding AE signals of 474, 279, and 287, respectively, involving 23, 21, and 22 System Organ Classes (SOCs). The report information for the three drugs tended to be consistent: more cases were reported in males than in females; the majority of patients were 65 years and over; AEs mostly occurred within 6\u00a0months of medication; the outcomes primarily consisted of hospitalization, prolonged hospital stay, and other serious adverse events; the primary reporting country was the United States. The most affected SOCs were infections and infestations, general disorders and administration site conditions, and blood and lymphatic system disorders.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The overall distribution of AEs for the three multiple myeloma proteasome inhibitors was consistent, but there were certain differences in specific AE signal characteristics, which should be noted in clinical applications.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1396378","type":"journal-article","created":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T04:40:23Z","timestamp":1725338423000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Signal mining of adverse events of proteasome inhibitors in multiple myeloma based on FAERS"],"prefix":"10.3389","volume":"15","author":[{"given":"Yuan","family":"Peng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaisen","family":"Shu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,9,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1080\/14740338.2017.1344212","article-title":"Safety of ixazomib for the treatment of multiple myeloma","volume":"16","author":"Bonnet","year":"2017","journal-title":"Expert Opin. Drug Saf."},{"key":"B2","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1080\/14740338.2018.1513487","article-title":"The safety of bortezomib for the treatment of multiple myeloma","volume":"17","author":"Cengiz Seval","year":"2018","journal-title":"Expert Opin. Drug Saf."},{"key":"B3","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/ejh.13240","article-title":"A comparative analysis of the safety profile of direct oral anticoagulants using the FDA adverse event reporting system","volume":"103","author":"DeLoughery","year":"2019","journal-title":"Eur. J. Haematol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.2174\/0929867323666160318173706","article-title":"Immunoproteasome-selective inhibitors: a promising strategy to treat hematologic malignancies, autoimmune and inflammatory diseases","volume":"23","author":"Ettari","year":"2016","journal-title":"Curr. Med. Chem."},{"key":"B5","doi-asserted-by":"publisher","first-page":"145","DOI":"10.19746\/j.cnki.issn1009-2137.2021.01.023","article-title":"Clinical characteristic, prognosis and treatment outcome of elderly multiple myeloma patients with impaired renal function","volume":"29","author":"Fan","year":"2021","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"B6","doi-asserted-by":"publisher","first-page":"977","DOI":"10.3892\/etm.2013.1261","article-title":"Therapeutic effects of autologous hematopoietic stem cell transplantation in multiple myeloma patients","volume":"6","author":"Fu","year":"2013","journal-title":"Exp. Ther. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1080\/10428194.2017.1376743","article-title":"Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study","volume":"59","author":"Goldschmidt","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"B8","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s12012-016-9378-7","article-title":"Molecular mechanisms of the cardiotoxicity of the proteasomal-targeted drugs bortezomib and carfilzomib","volume":"17","author":"Hasinoff","year":"2017","journal-title":"Cardiovasc Toxicol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e670","DOI":"10.1016\/S2352-3026(22)00165-X","article-title":"The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends","volume":"9","author":"Huang","year":"2022","journal-title":"Lancet Haematol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.7150\/ijms.55421","article-title":"Bullous pemphigoid and diabetes medications: a disproportionality analysis based on the FDA adverse event reporting system","volume":"18","author":"Huang","year":"2021","journal-title":"Int. J. Med. Sci."},{"key":"B11","doi-asserted-by":"publisher","first-page":"F451","DOI":"10.1152\/ajprenal.90576.2008","article-title":"The proteasome inhibitor bortezomib aggravates renal ischemia-reperfusion injury","volume":"297","author":"Huber","year":"2009","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","article-title":"Multiple myeloma epidemiology and survival: a unique malignancy","volume":"43","author":"Kazandjian","year":"2016","journal-title":"Seminars Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin. Proc."},{"key":"B14","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1182\/asheducation-2013.1.478","article-title":"Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: biological insights and early treatment strategies","volume":"2013","author":"Landgren","year":"2013","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"B15","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s13045-019-0807-5","article-title":"Incidence and mortality of multiple myeloma in China, 2006-2016: an analysis of the global burden of disease study 2016","volume":"12","author":"Liu","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.2147\/CMAR.S166640","article-title":"Treatment options for refractory\/relapsed multiple myeloma: an updated evidence synthesis by network meta-analysis","volume":"10","author":"Luo","year":"2018","journal-title":"Cancer Manag. Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12885-020-07741-0","article-title":"Immune checkpoint inhibitors-related myocarditis in patients with cancer: an analysis of international spontaneous reporting systems","volume":"21","author":"Ma","year":"2021","journal-title":"BMC Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1007\/s12185-008-0194-0","article-title":"Stromal cells in bone marrow play important roles in pro-inflammatory cytokine secretion causing fever following bortezomib administration in patients with multiple myeloma","volume":"88","author":"Maruyama","year":"2008","journal-title":"Int. J. Hematol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"218","DOI":"10.4274\/tjh.galenos.2021.2021.0052","article-title":"Post-marketing analysis of peripheral neuropathy burden with new-generation proteasome inhibitors using the FDA adverse event reporting system","volume":"38","author":"Mina","year":"2021","journal-title":"Turk J. Haematol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study","volume":"12","author":"Moreau","year":"2011","journal-title":"Lancet Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1111\/ejh.12342","article-title":"Bortezomib induces thrombocytopenia by the inhibition of proplatelet formation of megakaryocytes","volume":"93","author":"Murai","year":"2014","journal-title":"Eur. J. Haematol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12964-023-01433-5","article-title":"Interplay between proteasome inhibitors and NF-\u03baB pathway in leukemia and lymphoma: a comprehensive review on challenges ahead of proteasome inhibitors","volume":"22","author":"Pakjoo","year":"2024","journal-title":"Cell Commun. Signal"},{"key":"B23","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1002\/hep.29215","article-title":"Pentraxin-3 modulates lipopolysaccharide-induced inflammatory response and attenuates liver injury","volume":"66","author":"Perea","year":"2017","journal-title":"Hepatology"},{"key":"B24","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1200\/JCO.2005.11.030","article-title":"Proteasome inhibition as a novel therapeutic target in human cancer","volume":"23","author":"Rajkumar","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/SPC.0000000000000266","article-title":"Proteasome inhibitor-induced gastrointestinal toxicity","volume":"11","author":"Stansborough","year":"2017","journal-title":"Curr. Opin. Support. Palliat. care"},{"key":"B26","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1177\/1078155212470388","article-title":"Carfilzomib: a new proteasome inhibitor for relapsed or refractory multiple myeloma","volume":"19","author":"Steele","year":"2013","journal-title":"J. Oncol. Pharm. Pract."},{"key":"B27","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1002\/jgh3.12585","article-title":"Systemic quinolones and risk of acute liver failure I: analysis of data from the US FDA adverse event reporting system","volume":"5","author":"Taher","year":"2021","journal-title":"JGH Open"},{"key":"B29","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ejca.2016.07.025","article-title":"Infection risk with immunomodulatory and proteasome inhibitor\u2013based therapies across treatment phases for multiple myeloma: a systematic review and meta-analysis","volume":"67","author":"Teh","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"B30","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jaccao.2019.08.002","article-title":"AL amyloidosis for the cardiologist and oncologist: epidemiology, diagnosis, and management","volume":"1","author":"Witteles","year":"2019","journal-title":"JACC CardioOncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"888","DOI":"10.3390\/ijms22020888","article-title":"Pathological mechanisms of bortezomib-induced peripheral neuropathy","volume":"22","author":"Yamamoto","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B32","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s40360-023-00702-w","article-title":"A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS)","volume":"24","author":"Zou","year":"2023","journal-title":"BMC Pharmacol. Toxicol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1396378\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T04:40:26Z","timestamp":1725338426000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1396378\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,3]]},"references-count":32,"alternative-id":["10.3389\/fphar.2024.1396378"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1396378","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,3]]},"article-number":"1396378"}}